沙美特罗氟替卡松联合蒲地蓝口服液治疗慢性阻塞性肺疾病患者的临床疗效  

Clinical efficacy of salmeterol fluticasone combined with Pudilan oral liquid in the treatment of patients with chronic obstructive pulmonary disease

作　　者：刘力新 郭园园 刘方建 LIU Lixin;GUO Yuanyuan;LIU Fangjian(Department of Respiratory Medicine,Juye County People's Hospital,Heze,Shandong,274900,China)

机构地区：[1]巨野县人民医院呼吸内科,山东菏泽274900

出　　处：《当代医学》2023年第15期30-33,共4页Contemporary Medicine

摘　　要：目的探讨沙美特罗氟替卡松联合蒲地蓝口服液治疗慢性阻塞性肺疾病患者的临床疗效。方法选取2019年6月至2021年1月本院收治80例慢性阻塞性肺疾病患者作为研究对象,按照随机数字表法分为对照组与观察组,每组40例。对照组给予蒲地蓝口服液治疗,观察组给予沙美特罗氟替卡松联合蒲地蓝口服液治疗。比较两组血气指标[包括动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))]、肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]、临床疗效及并发症发生率。结果观察组PaCO_(2)低于对照组,PaO_(2)高于对照组,差异有统计学意义(P<0.05)。观察组FEV1、FVC、FEV1/FVC均大于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组并发症发生率比较差异无统计学意义。结论沙美特罗氟替卡松联合蒲地蓝口服液治疗慢性阻塞性肺疾病效果显著,可增强患者肺功能,改善其血气指标,安全性较高,值得临床推广应用。Objective To explore the clinical efficacy of Salmeterol fluticasone combined with Pudilan oral liquid in the treatment of patients with chronic obstructive pulmonary disease.Methods 80 patients with chronic obstructive pulmonary disease admitted to our hospital from June 2019 to January 2021 were selected as research subjects,and they were divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The control group was treated with Pudilan oral liquid,and the observation group was treated with salmeterol fluticasone combined with Pudilan oral liquid.The blood gas indexes(arterial partial pressure of carbon dioxide[PaCO_(2)],arterial partial pressure of oxygen[PaO_(2)]),pulmonary function indexes(the ratio of forced expiratory volume in one second[FEV1],forced vital capacity[FVC],FEV1/FVC),clinical efficacy and complication rate were compared between the two groups.Results The PaCO_(2)in the observation group was lower than that in the control group,and PaO_(2)was higher than that in the control group,the differences were statistically significant(P<0.05).The FEV1,FVC and FEV1/FVC in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in complication rate between the two groups.Conclusion Salmeterol fluticasone combined with Pudilan oral liquid has significant effect in the treatment of chronic obstructive pulmonary disease,which can enhance the lung function of patients,improve their blood gas indexes,and has high safety,which is worthy of clinical promotion and application.

关 键 词：慢性阻塞性肺疾病 沙美特罗氟替卡松 蒲地蓝口服液 

分 类 号：R563.9[医药卫生—呼吸系统]